- ►diabetesjournals.org I Goldstein, JM Young, J Fischer, K Bangerter, … - Diabetes Care, 2003 - Am Diabetes Assoc RESULTS—After 12 weeks of treatment, a dose-dependent (P = 0.02) improvement
in erections was noted for the GAQ, with 57 and 72% of men taking 10 mg or 20 mg
vardenafil, respectively, reporting improved erections, in contrast to 13% ... Cited by 186 - Related articles - BL Direct - All 5 versions
S de Tejada… - Diabetes Care, 2002 - Am Diabetes Assoc RESEARCH DESIGN AND METHODS—Men with type 1 or type 2 diabetes and a minimum
3-month history of ED were randomly allocated to one of three groups: placebo (n
= 71), tadalafil 10 mg (n = 73), or tadalafil 20 mg (n = 72) taken up to ... Cited by 179 - Related articles - BL Direct - All 5 versions
G Brock, A Nehra, LI Lipshultz, GS Karlin, M … - The Journal of urology, 2003 - Elsevier Of the intent to treat population 70% had severe ED (erectile function less than
11) at baseline. After 12 weeks both vardenafil doses were significantly
superior to placebo (p <0.0001) for all efficacy variables. Improved ... Cited by 172 - Related articles - BL Direct - All 10 versions
WJG Hellstrom, M Gittelman, G Karlin, T … - Journal of andrology, 2002 - Am Soc Andrology Erectile dysfunction (ED) has been reported to affect as many as 20 to 30
million men in the United States and 152 million men worldwide (NIH Consensus
Conference, 1993; Feldman et al, 1994; Ayta et al, 1999). The risk for ED ... Cited by 207 - Related articles - All 4 versions
C Stief, H Porst, I Saenz De Tejada, E Ulbrich … - International journal of clinical practice, 2004 - interscience.wiley.com This randomised, double-blind study assessed the long-term efficacy and
tolerability of vardenafil 10 and 20 mg in men with erectile dysfunction (ED). A
total of 566 men who completed an initial 12-month treatment period entered ... Cited by 60 - Related articles - BL Direct - All 5 versions
WJG Hellstrom, M Gittelman, G Karlin, T … - Urology, 2003 - Elsevier FIGURE 1/AUDIO CLIP 1. Mechanism of action of phosphodiesterase type 5 (PDE 5)
inhibitors. Nitric oxide (NO) derived from nonadrenergic/noncholinergic (NANC)
nerves, or from endothelial cell–derived NO synthase (eNOS) releases NO, ... Cited by 78 - Related articles - All 6 versions
BGA Stuckey, MN Jadzinsky, LJ Murphy, F … - Diabetes Care, 2003 - Am Diabetes Assoc RESULTS—Improvements in mean scores from baseline to end-of-treatment for IIEF
Q3 (35.7 vs. 19.9%) and Q4 (68.4 vs. 26.5%) were significant in patients
receiving sildenafil compared with those receiving placebo (P = 0.0001). ... Cited by 92 - Related articles - BL Direct - All 6 versions
MS Rendell, J Rajfer, PA Wicker, MD Smith - Jama, 1999 - Am Med Assoc You are seeing this message because your Web browser does not support basic Web
standards. Find out more about why this message is appearing and what you can do
to make your experience on this site better. ... Add to CiteULike Add to ... Cited by 353 - Related articles - BL Direct - All 4 versions
N Ishii, K Nagao, K Fujikawa, T Tachibana, … - International Journal of Urology, 2006 - interscience.wiley.com Aim: Vardenafil is a highly selective and potent phosphodiesterase type-5
inhibitor for the treatment of erectile dysfunction (ED). The efficacy of
vardenafil has been demonstrated in a broad range of ED populations, but ... Cited by 12 - Related articles - BL Direct - All 5 versions
D Hatzichristou, F Montorsi, J Buvat, N … - European urology, 2004 - Elsevier Results: The IIEF-EF domain score significantly improved from a baseline of
moderate ED (12.6–13.1) to mild ED in men on vardenafil (21.0–24.2) compared
with placebo (13.7–15.6) at weeks 4, 8, 12, and last observation carried ... Cited by 59 - Related articles - All 3 versions
